Beta-lactams were given in 45.5% of cases when an antibiotic was prescribed. Beta-lactams are the preferred treatment for many infectious syndromes, the authors noted.

The FDA has given the green light to Exblifep, based on long-established beta-lactam antibiotic cefepime and a new extended-spectrum beta-lactamase inhibitor (BLI) called enmetazobactam ...